Tamoxifen is a synthetic antiestrogen with both agonist and antagonist
properties. It is believed to act primarily through binding to estrog
en receptors in breast cancer cells, acting as a competitive inhibitor
of estrogen. Tamoxifen has a wide range of systemic effects, possibly
acting on every estrogen target tissue in the body. Tamoxifen therapy
is associated with a significant reduction in the risk of recurrence
and death in postmenopausal women with early stage breast cancer. In a
ddition, it has been shown to effectively suppress preclinical breast
cancer, as evidenced by the decrease in second primary breast cancers
in adjuvant trials. Tamoxifen is also the most widely used endocrine t
herapy for women with metastatic breast cancer. Tamoxifen, acting pred
ominantly as an estrogen agonist in the liver, has generally favourabl
e effects on serum lipids in postmenopausal women. In addition, tamoxi
fen has been shown to preserve bone mineral density and may even decre
ase the risk of osteoporosis in these women. Most patients treated wit
h tamoxifen have minimal adverse effects. Vasomotor symptoms are the m
ost commonly reported events. Less frequently, vaginal discharge or dr
yness, nausea and depression have been reported. A slight increase in
thromboembolic events in postmenopausal women taking tamoxifen has bee
n suggested in some adjuvant trials. Rarely, ocular toxicity and hepat
otoxicity are found. The adverse effect of primary importance is the i
ncreased incidence of endometrial carcinoma. Several studies indicate
that almost all of the tumours are of low histological grade and stage
, similar to those seen with exogenous estrogen use. The relative risk
of endometrial cancer in women taking tamoxifen is about 2 to 4 times
higher than for postmenopausal women not taking tamoxifen. The benefi
ts of tamoxifen outweigh the risks in almost all postmenopausal women
with estrogen receptor-positive early stage breast cancer and in all w
omen with metastatic breast cancer. Should tamoxifen prove to be an ef
fective chemopreventive agent for breast cancer, the risks and benefit
s of treatment wilt have to be more carefully assessed for this settin
g.